A Study On The Impact Of The Additional Deduction Policy On The W Biopharmaceutical Enterprise Innovation Chain

As China's economy has entered a new stage,and economic growth has entered a new normal,in the context of China's innovation-driven development strategy,the key way for enterprises to improve their independent innovation capabilities is research and development activities.As a typical high-tech enterprise,a bio-pharmaceutical company is a knowledgeintensive and innovative industry that is related to the physical and mental health of the people.It is very important for the development of enterprises to continue to invest in R & D expenses and effectively improve innovation output and innovation efficiency.However,the R & D activities of biopharmaceutical companies are characterized by long cycles,high risks,and uncertain returns.Governments in various countries have continuously formulated and improved a series of tax preferential policies and government subsidies to encourage R & D and innovation,especially the R & D expenses plus The deduction preferential policy is included,which is a tax-based preferential policy for corporate income tax.The purpose of the additional deduction policy is to guide and incentivize enterprises to increase R & D expenditure innovation input,improve R & D conditions,increase innovation output capacity,and create more innovation benefits for enterprises.The policy of additional deductions has been continuously upgraded,and Caishui [2015] No.119,Caishui [2017] No.34,and Caishui [2018] No.99 have been continuously implemented from 2016 to 2019.Here we will Caishui [2015] No.119,Caishui [2017] Circular 34 and Caishui [2018] Circular 99 are called new deduction policies.The new policy on R & D expense deductions has made important reforms on key issues such as the rate of deductions,collection of R & D expenses,accounting methods,and the scope of application of enterprises.How the effectiveness of the New Deal remains to be tested and the direction of policy development is also worth discussing.This article selects W biopharmaceutical enterprises as a typical case,and strives to deepen the impact of the new policy of the additional deduction policy Caishui [2015] Circular 119,Caishui [2017] Circular 34 and Caishui [2018] Circular 99,Multi-dimensional inquiry.Through the three dimensions of "innovation input-innovation output-innovation benefit" from the perspective of the enterprise innovation chain,analysis and implementation of the implementation and effect of the new policy deduction of the new policy,whether the policy can encourage companies to increase R & D costs by reducing the company's R & D costs Input,improve the intensity of R & D,thus have a positive impact on the innovation output of the enterprise and improve its innovation efficiency? How does the improvement of innovation efficiency achieve a higher input-output ratio for enterprises? Finally,the W bio-pharmaceutical companies found the existing problems in the R & D expense deduction process,and put forward suggestions and strategies,from small to large,with a view to standardizing the R & D cost deduction process for W bio-pharmaceutical companies and other companies to improve Independent innovation capability provides factual basis and experience reference.It is hoped that through the research in this article,we can provide relevant suggestions on how companies use the New Deal to promote R & D and innovation and how the government can better promote the implementation of new policies.